Drug news
Truvada filed at FDA for reduction in HIV Risk
Gilead Sciences has submitted a supplemental new drug application to the FDA seeking approval of once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) as a pre-exposure prophylaxis (PrEP) therapy to reduce the risk of HIV-1 infection among uninfected adults. The application is based on the iPrEx trial where Truvada reduced HIV risk in men by 44% versus placebo and up to 73% for men taking the drug consistently. In the Partners PrEP trial, Truvada reduced HIV risk in hetrosexuals by 73% versus placebo.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins